Table 1 Clinical data in malignant and non-malignant IPMNs

Total (n = 151)

Malignant IPMN

(n = 47)

Non-malignant

IPMN

(n = 104)

P

Total (n = 75)

Malignant IPMN

(n = 19)

Non-malignant

IPMN

(n = 56)

P

Age

63.28 ± 9.47

63.59 ± 8.99

62.60 ± 10.50

0.55

64.8 ± 8.90

68.42 ± 8.25

63.68 ± 8.86

0.44

Size

3.69 ± 1.98

3.93 ± 1.63

3.58 ± 2.11

0.34

3.1 ± 1.12

3.8 ± 1.33

2.5 ± 0.93

0.02

Sex(male/female)

95/56

34/13

61/43

0.11

49/26

11/8

38/18

0.43

Dysplasia

/

/

Low-intermediate grade

104

/

104

56

0

56

High-grade

24

24

0

11

11

0

Invasion

23

23

0

8

8

0

Type

< 0.01

< 0.01

Main

24

16

8

14

8

6

Branch

73

9

64

46

6

40

Mixed

54

22

32

15

5

10

Location

0.11

0.94

Head-neck

95

34

61

41

9

32

Body and Tail

56

13

43

34

10

24

CEA (ng/ml)

3.57 ± 3.61

4.75 ± 5.65

3.03 ± 1.95

0.09

3.99 ± 10.03

8.51 ± 19.29

2.43 ± 1.59

0.03

CA19-9 (U/ml)

48.68 ± 228.65

99.04 ± 396.08

26.19 ± 70.67

0.002

71.37 ± 204.27

132.83 ± 270.4

50.15 ± 174.53

0.13

HDL-c (mmol/L)

1.19 ± 0.39

1.10 ± 0.52

1.21 ± 0.31

0.38

1.02 ± 0.39

0.84 ± 0.41

1.08 ± 0.37

0.02

HDL-c < 0.7

9

7

2

< 0.01

12

9

3

< 0.01

LDL (mmol/L)

2.51 ± 0.82

2.52 ± 0.69

2.51 ± 0.89

0.95

2.27 ± 0.69

1.91 ± 0.65

2.40 ± 0.67

0.01

MPD diameter

0.61 ± 0.41

0.90 ± 0.49

0.48 ± 0.29

< 0.001

0.97 ± 0.42

0.43 ± 0.21

< 0.01

Pancreatitis

3

0

3

0.24

1

0

1

0.25

Diabetes

23

9

14

0.13

4

1

3

1.0

Lymph node metastasis (yes vs. no)

2

2

0

0.09

0

0

/

Peripancreatic extension

5

5

0

0.003

1

1

0

0.45

Mural nodule

17

13

4

< 0.01

8

5

3

0.01